Congressional Action On Drug Pricing Blueprint Likely To Be Modest
Senate Health, Education, Labor and Pensions Committee Chair Lamar Alexander noted panel's lack of consensus on drug pricing policies advanced by the Trump Administration during June 12 hearing.
You may also be interested in...
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.
Member companies’ direct-to-consumer TV ads will direct patients to information about drug costs – including list price, estimated out-of-pocket costs for the drug, and availability of financial assistance – under a voluntary program that takes effect in April 2019; initiative falls short of mandatory list price disclosures proposed by Trump Administration.